AbCellera Biologics' stock experienced a pre-market plunge of 5.47% on Tuesday, extending losses following the release of its first-quarter 2026 financial results.

Despite beating analyst expectations for both earnings per share and revenue, investor concerns appear to focus on the company's ongoing substantial losses and increased research spending. The company reported a net loss of $43.2 million for the quarter, which narrowed from $45.6 million a year earlier but still represented significant red ink.

Market reaction was negative due to rising research and development expenses, which climbed to $46.7 million from $42.5 million a year ago, and a decrease in the number of downstream programs led by partners to 40 from 44 at the end of the previous quarter. While the company announced positive interim Phase 1 clinical data for its ABCL635 candidate, investors focused on the challenging financial metrics.